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Abstract
Background: The single dose pneumonia ten-valent vaccine has been widely used and is highly efficacious against selected
strains Streptococcus pneumonia. A two-dose vial without preservative is being introduced in developing countries to
reduce the cost of the vaccine. In routine settings improper immunization practice could result in microbial contamination
leading to adverse events following immunization.
Objective: To monitor adverse events following immunization recommended for routine administration during infancy by
comparing the rate of injection-site abscess between children who received PCV-10 vaccine and children who received the
Pentavalent (DPT-HepB-Hib) vaccine.
Methods: A longitudinal population-based multi-site observational study was conducted between September 2011 and
October 2012. The study was conducted in four existing Health and Demographic Surveillance sites run by public
universities of Abraminch, Haramaya, Gondar and Mekelle. Adverse events following Immunization were monitored by
trained data collectors. Children were identified at the time of vaccination and followed at home at 48 hour and 7 day
following immunization. Incidence of abscess and relative risk with the corresponding 95% Confidence Intervals were
calculated to examine the risk difference in the comparison groups.
Results: A total of 55, 268 PCV and 37, 480 Pentavalent (DPT-HepB-Hib) vaccinations were observed. A total of 19 adverse
events following immunization, 10 abscesses and 9 deaths, were observed during the one year study period. The risk of
developing abscess was not statistically different between children who received PCV-10 vaccine and those received
Pentavalent (RR = 2.7, 95% CI 0.576–12.770), and between children who received the first aliquot of PCV and those received
the second aliquot of PCV (RR = 1.72, 95% CI 0.485–6.091).
Conclusion: No significant increase in the risk of injection site abscess was observed between the injection sites of PCV-10
vaccine from a two-dose vial without preservative and pentavalent (DPT-HepB-Hib) vaccine in the first 7 days following
vaccination.
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Introduction
PCV-10 is a 10-valent Pneumococcal Conjugate Vaccine active
against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F,
and 23F. It is manufactured by GlaxoSmithKline Biologicals
(GSK) to protect children against invasive pneumococcal disease
(IPD) and pneumococcal acute otitis media (AOM) caused by
serotypes included in the vaccine. PCV-10 vaccine has been
shown to be safe and does not cause adverse events beyond what is
common with current childhood vaccines [1–4].
Vaccines offered in multi-dose presentations can reduce the
cold-chain capacity requirements and medical waste handling
needs for introduction of new vaccines, as well as decrease the cost
per dose, but may pose potential safety concerns that are avoidable
with immediately disposable single-dose formats [5]. Multi-dose
vaccines have traditionally contained a preservative to minimize
the risk of contamination, but there have also been public safety
concerns raised about preservatives [6]. A two-dose preservative-
free vial presentation can reduce the programmatic capacity
requirements related to the introduction of a new vaccine while
addressing the public safety concerns with regard to preservatives.
Non-sterile injection practice or use of a two-dose preservative-free
vial after the recommended amount of time (6 hours) from
opening the vial could result in unsafe injections.
Pharmacovigilance is an important mechanism for evaluating
new vaccines globally and most suspected Adverse Events
Following Immunizations (AEFIs) are reported from passive safety
surveillance systems in developed countries. For developing
countries, WHO has provided guidelines for establishing immu-
nization safety surveillance [7], but WHO estimates that at least
65% of the world’s populations live in countries still lacking a
functional pharmacovigilance system [8]. Thus potential AEFIs
may not be detected through routine surveillance systems in
developing countries. Thus, designing a mechanism for evaluating
and proper monitoring of AEFIs is, therefore, very key in the
introduction of new vaccines.
The low incidence of most AEFIs and the low specificity of
existing disease detection systems also make identification and
interpretation of suspected AEFIs challenging. For example, there
are limited data available that describe the baseline incidence of
injection-site abscesses. In a US passive AEFI surveillance system
reporting on .1–9 billion net doses of human vaccine, the risk of
adverse event reporting was 11.4/100,000 immunizations. Com-
monly reported adverse events included fever (in 25.8% of
reports), injection site hypersensitivity (in 15.8%), injection site
oedema (in 10.8%) and vasodilation (in 10.5%); 426 cases of
injection-site abscesses were identified which comprised 0.3% of
all adverse event reports suggesting a risk of 3.4 per 10 million
immunizations [9]. Other safety studies for yellow fever vaccina-
tion and Bacille Calmette-Gue´rin (BCG) vaccination in Ivory
Coast and Australia also reported low rates of injection-site
abscesses [10].
This study was conducted to examine whether the use of a two-
dose preservative-free vaccine given in the routine immunization
program in Ethiopia is associated with excess adverse event
following immunization. The two-dose preservative-free vaccine
was given at the same time Pentavalent vaccine is given to children
under the age of one year. The hypothesis is that if correct
vaccination procedures are followed, the risk of injection-site
abscess would show no statistically significant difference between
children received the preservative-free PCV-10 vaccine and a fully
liquid one dose vial Pentavalent (DTP-Hib-HepB) vaccine.
Similarly, the risk of injection-site abscess would show no
statistically significant difference between children received first
aliquot given from a two-dose PCV-10 vaccine vial and those
received the second aliquot from the same vial.
Subjects and Methods
The study was conducted in four woredas (districts) located in
four regions of the country that have existing University based
Health and Demographic Surveillance System (HDSS). These
HDSS are Kersa from Haramya University, Eastern Hararghe,
Oromia Region; Dabat from the University of Gondar, North
Gondar Zone, Amhara region; Arbaminch Zuria from Arba
Minch Univerisy, Southern Nations Nationality and People
Region; and Kiliete Awlaelo from Mekelle University, Eastern
Tigray Zone, Tigray Region. For the purpose of census and other
statistical data collection, kebeles (smallest administration units) are
further divided into enumeration areas (EA). At all levels there are
personnel responsible for providing services. At the kebele level,
there are two Health Extension Workers (HEWs) responsible for
organizing preventive services and maintain household records
that are routinely updated annually. At the EA level, there are
several community volunteers who assist the HEWs.
A longitudinal population-based multi-site observational study
was conducted between September 2011 and October 2012. Data
on vaccines received and adverse events following immunization,
such as injection-site abscess, shock or death, were collected
systematically and prospectively. Eligible populations for the study
were children that are eligible to receive routine immunization at
vaccination centres in the study area. The specific inclusion
criteria include: resident of selected HDSS districts, provision of
informed consent and age ,1 year. For children who fulfill the
inclusion criteria the only exclusion criterion for the study was
receiving concomitant experimental vaccine/intervention.
The sample size calculation was made based on the following
assumptions: detecting a relative risk of 2.0, baseline incidence of
abscess formation following vaccination of 0.001, a=0.01, power
of 80%, and intera class correlation (ICC) = 0.4. Accordingly,
approximately a minimum of 16, 500 vaccinated children were
needed. Considering a 15% non-response and drop-out rate, the
final sample size required for the study was approximately 19, 500
vaccinated children, i.e. 39,000 vaccine visits/episodes (assuming
an average of two visits per child) over the study period.
Data were collected using various data capture systems that
were based at vaccination centers, households and clinics.
Enumeration and Identification of Eligible Children
The study began by conducting a complete registration of the
children under the age of one year through house-to-house survey
in all the study sites to create a database of eligible study
population. Community interviewers initially visited all households
in the selected study sites to identify and record all children under
the age of one year. At this visit a photo ID with unique
identification number was issued to mothers of eligible infants.
Vaccination Center Surveillance
Vaccination information was collected using an improved
vaccination card that has space to record the time and date of
vaccination as well as the aliquot number (whether the dose was
the first or second from the vial) and the injection site (whether it
was on the left or right thigh). Designated health workers at
vaccination centres administered routine EPI vaccines to eligible
infants as per the guidelines provided by the FMOH. Accordingly,
PCV injections should be given on the right thigh and Pentavalent
injections should be given on the left thigh. Mothers enrolled in the
study were encouraged to carry the photo ID produced by the
PCV-10 and Injection Site Abscess
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study when seeking immunization services. Vaccines given to
eligible children are immediately recorded on the improved child
vaccination card and on the registration book at the facility. At the
time of vaccination health workers advised parents to return to the
health facility if AEFI such as an injection-site abscess is observed.
Clinical mentors were trained to use consistent case identification
between individuals and before and after identify abscess. Children
identified during home follow up with an injection-site abscess
following immunization with pentavalent vaccine or PCV-10
vaccine were considered suspect case of AEFI and were
investigated by trained clinical mentors. When injection-site
abscess was confirmed a digital photograph of the affected limb
was obtained as a permanent record of the event.
Household-based Surveillance
A household-based surveillance was the key component of the
study. When registered children receive vaccine, follow up is
initiated to observe whether the child develops AEFI or not.
Community interviewers were trained to observe and screen for
injection-site abscesses using uniform follow up visit forms. The
community interviewers immediately notify suspect cases to the
clinical mentor of the study. The clinical mentor visits the reported
child immediately and if confirm the presence of abscess the child
is immediately referred to the nearest referral health facility for
further evaluation and treatment. If the AEFI is death, verbal
autopsy was done to determine the cause of death using
standardized verbal autopsy procedure after the traditional
mourning period, which is about 45 days, to obtain additional
information surrounding the death but not with the assumption of
getting a definitive cause of death.
Hospital-based Surveillance
A system to capture information on all hospitalized children that
are eligible for the study was established in collaboration with the
local and referral health facilities. The hospital surveillance was
established to identify children hospitalized due to shock/severe
illness following immunization. The study established this proce-
dure before the introduction of PCV-10 vaccine in the locality.
The clinical mentor visited health facilities weekly to inquire about
admitted suspect cases or when AEFI is notified. All the data from
the different sources were linked using a unique identification
number.
Four different types of form were used to capture the required
data. The first was household registration form: The registration form
Figure 1. Risk of Injection site abscess for PVC-10 and Pentavelent Vaccinations, Ethiopia, 2011/2012. Key: Risk of Injection site
Abscess in % with 95% Confidence Interval.
doi:10.1371/journal.pone.0097376.g001
Figure 2. The relative risks for Injection site abscess for PVC-10 compared to Pentavelent and for PCV-10 first and second aliquot
Vaccinations, Ethiopia, 2011/2012. Key: Relative Risk with 95% Confidence Interval.
doi:10.1371/journal.pone.0097376.g002
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collects information about the household and the demographic
characteristics of the eligible children. The household registrations
were updated every two months by visiting all households in the
study areas. The second was Vaccination Card: an addendum card to
existing vaccination card was implemented in all vaccination
centres in the study areas to collect information on the time and
date of vaccination, type of aliquot the child received, injection
site, and other vaccinations provided during the same session. The
modified vaccination card was an attachment to existing
immunization card so that any previous history of vaccination
can also be tracked. The third was Household follow up form:
community interviewers’ use this form for following vaccinated
children at home at 48 hours and on the 7th day. The last form
was AEFI Event Form: this form is completed for all children suspect
for AEFI and has two sections. The first part that identifies the
child was filled by the community interviewers and the second part
was completed by the clinical mentor who examined the child
AEFI events. Any AEFI confirmed by the clinical mentor was
promptly reported. Digital photograph was obtained of the
affected limb as a permanent record of the event and stored
without personal identifying image or information.
To ensure the quality of data an extensive supervision scheme
was put in place for all sources of data. Each level performed as
per standard procedure and reported any irregularities immedi-
ately. Researchers themselves did extensive field supervision on a
regular basis. Training manual was prepared and training was
given by survey experts and clinicians for five days to all site
researchers and field workers to standardize procedures. The
training included basic principles of interviewing and surveillance,
detecting and reporting AEFIs, follow up procedures, ethical
conduct of research, and referral procedures.
Data from each source were cleaned, standardised, collated and
merged (on personal ID number) to create a database of events,
specific to each site, which provides temporal links between
immunization events and potential adverse events. Data entry was
done immediately after the second follow up (7th day) was
completed for the vaccinated children. Data were examined by the
data manger for consistency and data validation procedures were
also integrated with data entry system to minimize errors during
data entry.
The specific study objectives directed the data analysis. The
major endpoints were injection site abscess and death. Compar-
ison of the risk of injection site abscess on the left and right thigh to
detect difference in abscess risk between PCV and Penta injections
was done by computing the Relative Risk along with its 95%
Confidence Interval. Comparison of the risk of injection site
abscess among children receiving the first aliquot and second
aliquot of PCV was made to detect difference in abscess risk
between the two aliquots. Deaths were described based on the
household surveillance and verbal autopsy.
Ethics Statement
The study was reviewed and approval by the National Ethical
Review Board of Ethiopia. The study in itself did not introduce
any new procedure in the immunization programme. There were
no risks associated with the research as it mainly did interview and
follow by observation. Written informed consent was obtained
from the mother/guardian of vaccinated children. Confidentiality
was maintained by using unique identifiers. Children identified
with AEFI were immediately referred and transported to the
nearest health facility for appropriate case management.
Results
A total of 55,268 vaccination episodes were observed during the
one year study period. Of which 28,321(51.2%) were male and
26,947(48.8%) were female. Majorities (51.6%) were under two
months old and only 3.9% were older than ten months (Table 1).
The study observed 55,268 PCV, and 37,480 Pentavalent (DPT-
Table 3. The distribution of PCV aliquot given to children enrolled into the study, Ethiopia, 2011/2012.
Study sites PCV Injection Total
1st aliquot 2nd aliquot
Arbaminch 8113 (53.5%) 7051 (46.5%) 15164
Dabat 4837 (56.2%) 3769 (43.8%) 8606
Kersa 9166 (53.0%) 8130 (47.0%) 17296
Kilite Awlaelo 7378 (52.1%) 6785 (47.9%) 14163
Total 29494 (53.4%) 25735 (46.6%) 55229
doi:10.1371/journal.pone.0097376.t003
Table 4. The distribution of the site of PCV injection among the study children, Ethiopia, 2011/2012.
Study sites PCV vaccination Penta Vaccination
Right thigh Left thigh Right thigh Left thigh
Arbaminch Zuria 15120 (99.7%) 50 (0.3%) 249 (2.6%) 9160 (97.4%)
Dabat 8594 (99.8%) 13 (0.2%) 40 (0.7%) 5525 (98.3%)
Kersa 17131 (99.4%) 111 (0.6%) 162 (1.1%) 14448 (98.9%)
Kilite Awlaelo 14145 (99.8%) 22 (0.2%) 73 (0.9%) 7977 (99.1%)
Total 54990 (99.6%) 196 (0.4%) 524 (1.4%) 37110 (98.6%)
doi:10.1371/journal.pone.0097376.t004
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Hep.B-Hib) vaccination episodes during the one year study period,
which was higher than the sample size planned at the design stage.
All children who received Pentavalent received PCV vaccination
at the same time, while a total of 17,788 received only PCV
vaccination. Of the total 55,268 PCV vaccinations 22,067 were
PCV1, 18,718 PCV2, and 14,483 PCV3. Of the total 37,480
Pentavalent (DPT-Hep.B-Hib) vaccinations 12,912 were Penta1,
12,776 Penta2, and 11,792 Penta3 (Table 2). All vaccinated
children in the study sites were visited at home at 48 hours and on
the 7th day following vaccination by the designated field workers.
In all study sites, children who received the first aliquot (53.4%)
of the PCV were slightly higher than those who received the
second aliquot (46.6%). This is anticipated as health workers are
expected to discard the 2nd aliquot if not used within 6 hours. The
proportion of the first and second aliquot PCV vaccine offered to
eligible children is similar across the four study sites (Table 3).
Overall 99.6% of the PCV injections were given on the right
thigh and 98.6% of the Pentavalent injections were given on the
left thigh as recommended (Table 4). Oversight regarding the
correct administration of the vaccine on the recommended side of
thigh occurred only when a single vaccine is provided to the child.
A total of 19 adverse events following immunization were
observed during the follow up period; up to 7 days following
immunization. Of which 10 were abscess and 9 were death. Seven
of the ten abscess cases received only PCV vaccine and the rest
three received both PCV and Pentavalent at the same time. All
abscess cases were treated at health facilities and all fully recovered
following appropriate treatment. Among the total 19 AEFIs, 11 of
them were male and 8 were female. Moreover, 14 of them were
under 6 months old and the rest 5 were 7–12 months old (Table 5).
As shown in Figure 1 and 2, no statistically significant increased
risk of adverse events was observed between PCV and Pentavalent
(DPT-Hep.B-Hib) injection sites (RR=2.7; 95% CI 0.576–
12.770; P= 0.204) as well as between the first and second aliquot
of PCV injections (RR=1.15; 95% CI 0.287–4.582; P = 0.851).
The total number of deaths observed during the one year
surveillance period was 9. All deceased children, except 1, received
at least two different vaccines at the same time. Four of the deaths
were reported from Dabat, 3 from Kersa and 2 from Kilite
Awlaelo. No death was reported from Arbaminch. Four of the
deaths were male and the rest 5 were female. Seven of the nine
deceased children were younger than six months. Only two of the
deceased children were age seven and eleven months at the time of
death.
Discussions
The risk of injection site abscess was comparable in children
who received PCV-10 vaccine from a two-dose vial without
preservative up to 7 days following vaccination compared to those
who received pentavalent vaccine. The study also documented
that there is no increased risk of injection site abscess in children
who received the second aliquot of PCV-10 vaccine up to 7 days
following vaccination compared to those who received the first
aliquot.
Improper immunization practice with a two-dose preservative-
free vial could potentially result in microbial contamination, non-
sterile injections, and adverse events. Cognizant of such risks, the
Federal Ministry of Health of Ethiopia in partnerships with key
stakeholders conducted extensive training to familiarize the
immunization staff at all levels about the necessary procedures
on the proper use of the two-dose preservative-free vial. This is
believed to have prevented any potential risk during the
introduction of the new pneumonia vaccine in Ethiopia.
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This population based longitudinal study was necessary to
overcome the challenges in establishing the temporal relationship
between a suspected AEFI and the date of vaccine administration.
The study established an extensive network of vaccinators,
community interviewers and clinical mentors to gather detailed
information about the timing of vaccination and development of
AEFI. Thus, this is one of the systematic studies conducted in large
scale on immunization in Ethiopia that minimize recall and
ascertainment biases. Another very critical aspect of this study was
the control of potential confounders. Since the risk of adverse
effects following immunization for PCV and Penta were observed
in the same child there was no need to utilize other confounding
control strategies.
The study managed to enroll more than the expected number of
children into the study. That was possible because large
population base and the extra efforts made by the study teams
in creating awareness about the importance of immunization in
general during their home visits. The sensitization increase
immunization coverage and allowed the study to observe more
children than originally anticipated. The increased sample size in
turn increased the power of the study to detect differences, if there
were any.
As the number of deaths is very small further analysis to
determine the mortality risk difference was not possible, which was
a recognized limitation at the design stage. Verbal autopsy was
done to describe the cause of death suggested a probable vaccine
related cause only for one of the deaths. Determining a definitive
cause of death for any of the deaths was not possible because of
lack of facilities in rural Ethiopia; again a recognized limitation at
the design stage.
We conclude that if properly used as per the instruction of the
manufacturers to eligible children in the routine immunization,
preservative free two-dose vaccine vials cause no excess risk of
Adverse Events Following Immunization.
Acknowledgments
The research team would like to gratefully acknowledge the support
provided by the Federal Ministry of Health, the World Health
Organization country office and head quarters, the National PCV vaccine
introduction Coordinating Committee, and all partners involved in
facilitating the successful implementation of the study. The research team
also gratefully acknowledges Dr. Asnakew Yigzaw from JSI Washington,
Dr. Rober T. Chen from Clinical Trial Team CDC/DHAP/EB, and Dr.
Fikre Enquselassie from the School of Public Health of Addis Ababa
University for kindly agreeing to serve as independent reviewers for the
study. We wish to extend our sincere gratitude for Universities of
Arbaminch, Haramaya, Gondar and Mekelle for superb coordination of
the field activities. Finally, our highest gratitude goes to the entire field
workers in all four sites who implemented the field activities with
dedication. We are also highly indebted to all mothers who participated
in our study.
Author Contributions
Conceived and designed the experiments: YB Alemayehu Worku MD NT.
Performed the experiments: YB Alemayehu Worku MD NT NA WA BW
YK TS Amare Worku LO BM YA TT YD SM GA. Analyzed the data:
YB Alemayehu Worku MD NT NA WA BW YK TS Amare Worku LO
BM YA TT YD SM GA. Contributed reagents/materials/analysis tools:
YB Alemayehu Worku MD NT NA WA BW YK TS Amare Worku LO
BM YA TT YD SM GA. Wrote the paper: YB Alemayehu Worku MD
NT.
References
1. Tichmann SI, Soemantri P, Behre U, Disselhoff J, Mahler H, et al. (2005)
Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-
component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus
influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate
Vaccine. Pediatr Infect Dis J 24: 70–77.
2. Knuf M, Habermehl P, Cimino C, Petersen G, Schmitt HJ (2006)
Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal
conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/
Hib combination vaccine in healthy infants. Vaccine 24: 4727–4736.
3. Olivier C, Belohradsky BH, Stojanov S, Bonnet E, Petersen G, et al. (2008)
Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal
conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-
IPV-HBV-Hib combination vaccine in healthy infants. Vaccine 25: 3142–3152.
4. Chevallier B, Vesikari T, Brzostek J, Knuf M, Bermal N (2009) Safety and
reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus
influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with
routine childhood vaccines. Pediatr Infect Dis J 28: 109–118.
5. Drain PK, Nelson CM, Lloyd JS (2003) Single-dose versus multi-dose vaccine
vials for immunisation programmes in developing countries. Bull World Health
Organ 81: 726–731.
6. Clements CJ, Wesselingh SL (2005) Vaccine presentations and delivery
technologies -what does the future hold? Expert Rev Vaccines 4: 281–287.
7. World Health Organization (1999) Immunisation safety surveillance: guidelines
for managers of immunisation programmes on reporting and investigating
adverse events following immunization. Manila, Philippines: World Health
Organization, Regional Office for the Western Pacific. 56 p.
8. Black S, Zuber PL (2009) Global trends and challenges in vaccine safety.
Pediatric Health 3: 329–335.
9. Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, et al. (2003)
Surveillance for safety after immunisation: Vaccine adverse event reporting
system (VAERS) – United States, 1991–2001. MMWR Surveillance Summaries
52: 1–24.
10. Fitzner J, Coulibaly D, Kouadio DE, Yavo JC, Loukou YG, et al. (2004) Safety
of the yellow fever vaccine during the September 2001 mass vaccination
campaign in Abidjan, Ivory Coast. Vaccine 23: 156–162.
PCV-10 and Injection Site Abscess
PLOS ONE | www.plosone.org 7 June 2014 | Volume 9 | Issue 6 | e97376
